DIA 2019 Global Annual Meeting

Component Type: Session
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-19-732-L04-P; CME 1.25; IACET 1.25; RN 1.25

This session will explore the state-of-the-science in regard to patient involvement in benefit-risk communication for medicinal products. Interactive audience engagement will occur throughout the session to stimulate dialogue on implications for advancing the science and practice in this area. Questions will include: • What steps are regulators taking to involve patients in benefit-risk communication? • What new tools are being developed to educate patients about the benefits and risks of drugs, and how effective are they? • What are the current challenges and barriers that impede greater patient involvement in benefit-risk communication of medicinal products? How can they be addressed? • What are promising avenues for further advancing the science of patient involvement in benefit-risk communication?

Learning Objectives

Describe the state-of-the-science in terms of patient involvement in benefit-risk communication of pharmaceutical products; Discuss challenges and solutions for enhancing patient involvement in benefit-risk communication and for improving how such information is provided to them; Identify pragmatic scientific approaches for enhancing patient involvement in benefit-risk communication and the role of new types of interactive digital educational tools for patients.

Chair

Meredith Y. Smith, PhD, MPA

Speaker

Trends in the Use of Interactive Digital Tools to Educate Patients Regarding Safe and Appropriate Use of Drugs: What Has Been Learned to Date?
Meredith Y. Smith, PhD, MPA

Patient Engagement in Pharmacovigilance and Benefit-Risk Communication: Update from EMA
Tânia Teixeira, PharmD

Involving Patients in Benefit-Risk Communication: What are the Opportunities? What are the Challenges?
Marc M. Boutin, JD